ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids
Nina Hedemann(Christian-Albrechts-Universität zu Kiel), Dirk Bauerschlag(Christian-Albrechts-Universität zu Kiel)
Cited by 32
Related Papers
ADAM17 inhibition enhances platinum efficiency in ovarian cancer
|Oncotarget|2018|27
Newly Developed Dual Topoisomerase Inhibitor P8-D6 is Highly Active in Ovarian Cancer
|Research Square|2021|1
Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma
|International Journal of Molecular Sciences|2025|0